Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...

Leerink lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Market Perform rating on the shares after ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...

EST Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals (RXRX) todayDiscover the Best Stocks and Maximize Your ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -47.22% and 84.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Recursion Pharmaceuticals shares were down 7% to $7.12 after the company reported a fourth-quarter loss that was wider than analysts expected.

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for ...

On Friday, TD Cowen maintained a Hold rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX), as the stock experiences significant pressure with a 17.35% decline over the past week.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...